Which patients do you think would benefit most from xanomeline-tropsium (Cobenfy) monotherapy?  

What we know best about this new drug, Cobenfy, a xanomeline-trospium combination, is that it does not directly affect the dopamine receptor, so it is novel and a new antipsychotic drug. And its antipsychotic efficacy has been demonstrated and accepted by the FDA. But still, we have a rather ‘pure...

Xanomeline-trospium combination is not associated with weight gain/metabolic adverse effects, drug-induced movement disorders, sedation/somnlence, hyperprolacinemia, or prolongation of the ECG QT interval. Patients who cannot tolerate antipsychotics because of these issues may benefit from monothera...